Finding Description
Based on interview, and record review, the facility failed to ensure 4 of 8 sampled residents (Residents 3, 8, 25, and 37) who received psychotropic drugs (any drug that affects brain activities associated with mental processes and behavior), or antipsychotic drugs (drugs that work by altering brain chemistry to help reduce psychotic symptoms including hallucinations, delusions, and disordered thinking) had adequate diagnoses and clinical indications for use including monitoring of target behaviors to assess effectiveness, monitoring of adverse side effects, and documentation by the physician that included the rationale, and duration for as needed (PRN) psychotropic drugs that exceeded 14-days.
This resulted in or had the potential to result in residents receiving unnecessary medication with adverse side effects, some of which could include permanent neurological side effects, and a deterioration in the clinical condition of these residents.
Findings:
1. A review of Resident 3's medical record indicated she was admitted with diagnoses that included lung disease, anxiety disorder, vascular dementia (form of dementia caused by an impaired supply of blood to the brain) with behavioral disturbances, and major depressive disorder.
A review of Resident 3's Physician Orders included an order, dated 11/29/21, for Zyprexa (antipsychotic medication) 7.5 milligrams (mg) daily at bedtime. There was no diagnosis or indication for use including specific target behavioral symptoms included in the order. No monitoring of adverse side effects could be located in the medical record.
During a concurrent interview, and record review, on 6/14/22 at 4:44 pm, the MDS (Minimum Data Set, resident assessment tool) Nurse, Licensed Nurse (LN) 3 confirmed the above Physician's Order for Zyprexa did not include a diagnosis, or indication for use or specific behaviors to monitor.
During a concurrent record review, and interview, on 6/15/22 at 10:02 am, the Pharmacy Consultant (Pharm) was asked about Resident 3's Physician's Order for Zyprexa, dated 11/29/21. The Pharm confirmed there was no diagnoses for the use of this drug, and said he had not identified any irregularity regarding this order during his medication regimen reviews.
During a concurrent interview, and record review, on 6/16/22 at 7:59 am, the Charge Nurse (CN) confirmed the diagnosis should be included in Resident 3's Physician Order, as well as the target behaviors. She confirmed the adverse side effects were not being monitored as they should for this resident, and other residents who received psychotropic medications. They noted this to be an issue, and new monitoring forms have been ordered that have this capability.
2. A review of Resident 8's medical record indicated, that she was admitted with diagnoses that included dementia with behavioral disturbance, schizoaffective disorder depressive type (combination of symptoms of schizophrenia, and mood disorder such as depression), and anxiety disorder. Resident 8 received Abilify (antipsychotic drug) for schizoaffective disorder. The consent for this drug included the following target behaviors: verbal outbursts, sadness, aggressive behavior during care, and accusatory statements.
During a concurrent interview, and record review, on 6/15/22 at 7:33 am, LN 3 confirmed the above behaviors were monitored for use of the drug Abilify. The behavior monitoring forms for Abilify indicated a 1 meant verbal outbursts. From 6/1/22 - 6/9/22 a 1 appeared on the day shift. LN 3 was asked how many verbal outbursts did Resident 8 have per day for those days. LN 3 reported that there should be a note with details about the behavior, and how many. From 6/1/22 - 6/9/22, there were no notes regarding behaviors, with the exception of 6/4/22, when there was a specific note about one behavior that shift. LN 3 agreed she was unable to tell if Resident 8 had just one behavior, of verbal outbursts, or more on the other days where there was no note. LN 3 said they have ordered different forms that have capability to enter the number of specific behaviors. LN 3 was asked about monitoring of adverse side effects of the psychotropic, and antipsychotic drugs this resident took, but she did not know if it was being done, or where it was documented, if done.
During a concurrent interview, and record review, on 6/16/22 at 7:43 am, CN confirmed the above. CN said the behavior monitoring was not accurate, and it was hard to tell exactly how many behaviors the Resident 8 had. CN also confirmed adverse side effects were not being monitored, as they should be. CN said they noted this to be an issue, and new monitoring forms have been ordered that have the capability to accurately monitor behaviors as well as side effects.
3. A review of Resident 25's medical record indicated, that he was admitted with diagnoses that included unspecified dementia with behavioral disturbances, delusional disorder (characterized by the presence of one or more nonbizarre delusions that persist for at least one month), and chronic pain.
A review of the Resident 25's Physician's Orders included an order, dated 4/4/22, for Xanax (anti-anxiety medication) 0.25 mg twice per day for anxiety, and a Xanax 0.5 mg PRN (as needed) order before changing, dated 11/1/21.
During a concurrent interview, and record review, on 6/14/22 at 4:57 pm, LN 3 confirmed that Resident 25's orders indicated Xanax was to be given for anxiety, although no anxiety disorder, was included in the list of diagnoses for this residents. The PRN order for Xanax was ordered on 11/1/21, and started on 11/2/21.
During a concurrent interview, and record review, on 6/15/22 at 8:52 am, the CN confirmed that Resident 25's physician had not documented a reason why the PRN Xanax needed to be extended past 14-days, and the duration.
During a concurrent interview, and record review, on 6/15/22 at 10:02 am, Pharm confirmed that he had not advised the physician of the need to re-evaluate the PRN Xanax after 14- days, and document the rationale as to why it should continue with the duration, in his medication regimen reviews for this Resident 25.
4. A review of Resident 37's medical record indicated, that he was admitted with diagnoses that included unspecified dementia with behavioral disturbance, insomnia, and lung disease. A review of the Resident 37's Physician's Orders included an order dated 5/17/22, for Remeron (anti-depressant) 30 mg at bedtime for dementia (Remeron is not approved to treat dementia). There was no specific behavioral symptoms included in this order. There was also an order dated 6/1/22, for Seroquel 125 mg three times per day for behavior disturbance. There was no diagnosis or indication for use, or specific behavioral symptoms included in this order.
During a concurrent interview, and record review, on 6/14/22 at 5:06 pm, LN 3 confirmed the above order for Remeron indicated its use was for dementia, and did not include specific behavior monitors. LN 3 confirmed there was no diagnosis included in the order for Seroquel, and no specific behaviors. During a subsequent interview, on 6/15/22 at 8:03 am, LN 3 said the consent for Seroquel listed behaviors as delusions and agitation. For Behavior monitoring a 1 was noted to be for delusions. A 1 was noted on 6/9/22, even though Resident 37 was noted to be combative and not having delusions on that day. CN who was also present, said the notes should include what happened for any behavior documented on the behavior monitoring sheet.
During a later interview, on 6/15/22 at 8:55 am, CN confirmed the diagnosis and behaviors should be included in the Physician's Order, and the behaviors on the physician's order and the consent should be the same. CN again confirmed the behavior monitoring was not accurate, and it was hard to tell exactly how many behaviors the resident had. CN also confirmed adverse side effects were not being monitored as they should be. CN said they noted this to be an issue, and new monitoring forms have been ordered that have the capability to accurately monitor behaviors as well as side effects.